Jasper Therapeutics, Inc. (JSPRW)
| Market Cap | 17.64M -78.2% |
| Revenue (ttm) | n/a |
| Net Income | -55.73M |
| EPS | -2.47 |
| Shares Out | 28.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.0110 |
| Previous Close | n/a |
| Day's Range | 0.0110 - 0.0110 |
| 52-Week Range | 0.0078 - 0.1456 |
| Beta | 3.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About JSPRW
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticar... [Read more]
News
Jasper Therapeutics trading resumes
17:45 EDT Jasper Therapeutics (JSPR) trading resumes
Jasper Therapeutics completes acquisition of Kira Pharmaceuticals
Jasper Therapeutics (JSPR) announced that Jasper has completed the acquisition of Kira Pharmaceuticals in an all-stock transaction. The combined company will focus on advancing a consolidated pipeline...
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders
Jasper Therapeutics trading halted, news pending
17:10 EDT Jasper Therapeutics (JSPR) trading halted, news pending
Jasper Therapeutics Proxy statement: Proxy filing
Jasper Therapeutics filed a proxy statement on June 15, 2026, providing details for shareholder voting and corporate governance matters.
Jasper Therapeutics Proxy statement: Proxy filing
Jasper Therapeutics filed a proxy statement on June 15, 2026, providing details for shareholder voting and corporate governance matters.
Jasper Therapeutics initiates review of strategic alternatives
Jasper Therapeutics (JSPR) announced that, following an evaluation of current market conditions, its board of directors has decided to initiate a review of strategic alternatives. Strategic alternativ...
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibod...
Jasper Therapeutics price target lowered to $3 from $4 at RBC Capital
RBC Capital lowered the firm’s price target on Jasper Therapeutics (JSPR) to $3 from $4 and keeps a Sector Perform rating on the shares. The firm continues to believe that…
Jasper Therapeutics downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Jasper Therapeutics (JSPR) to Hold from Buy without a price target The company is “now at a critical juncture,” the analyst tells investors in a research note.
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody...
Jasper Therapeutics Quarterly report: Q1 2026
Jasper Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Jasper Therapeutics Earnings release: Q1 2026
Jasper Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI
Evercore ISI lowered the firm’s price target on Jasper Therapeutics (JSPR) to $7 from $12 and keeps an Outperform rating on the shares. The firm adjusted targets for its small-to-mid…
Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)
“Briquilimab has demonstrated the potential for a compelling and differentiated profile in both CSU and CIndU, along with proof of concept in asthma,” said Jeet Mahal, President and CEO of…
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibo...
Jasper Therapeutics Earnings release: Q4 2025
Jasper Therapeutics released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
Jasper Therapeutics Annual report: Q4 2025
Jasper Therapeutics has published its Q4 2025 annual report on March 30, 2026.
Jasper Therapeutics assumed with a Neutral at UBS
UBS assumed coverage of Jasper Therapeutics (JSPR) with a Neutral rating and $1.50 price target UBS sees a balanced risk-reward over the next 12 months with competitive uncertainties, but dose…
Jasper Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Briquilimab showed rapid, deep disease control in urticaria and asthma studies, with a favorable safety profile and differentiated mechanism. Phase II-B/III trials in CSU and CIndU are planned, with dose selection focused on balancing efficacy and safety. Equity financing is likely for upcoming studies.
Jasper Therapeutics Slides: Corporate presentation
Jasper Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibod...
Jasper Therapeutics initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Mike King initiated coverage of Jasper Therapeutics (JSPR) with a Buy rating and $17 price target
Jasper Therapeutics Transcript: Study Result
Updated BEACON and open-label extension data show briquilimab delivers rapid, deep, and durable disease control in CSU and CIndU, with a favorable safety profile and low incidence of adverse events. Results support advancing to a phase 2b study in the second half of 2026.
Jasper Therapeutics Press release: Study Result
Jasper Therapeutics issued a press release on January 8, 2026, disclosing material business information to investors.